Can topiramate be given to a patient with glaucoma?

NO - Topiramate Should Be Avoided in Patients with Glaucoma

Phentermine/topiramate ER is contraindicated in patients with a history of glaucoma, and topiramate monotherapy poses significant risk for acute angle-closure glaucoma. 1

Why Topiramate is Dangerous in Glaucoma

Mechanism of Glaucoma Induction

Topiramate causes acute myopia with secondary angle-closure glaucoma through a unique mechanism 2:

• Supraciliary effusion leads to anterior displacement of the lens-iris diaphragm
• Results in anterior chamber shallowing and angle closure
• Symptoms typically occur within 1 month of initiating therapy (often within the first week)
• Can occur in both pediatric and adult patients

Clinical Evidence of Risk

The evidence consistently demonstrates elevated glaucoma risk:

• New users of topiramate have a 54% increased risk of glaucoma (RR = 1.54) 3
• First month of use carries a >7-fold higher risk compared to matched controls 1
• Risk returns to baseline after the first month in continuing users
• Multiple case reports document bilateral acute angle-closure requiring emergency intervention 4, 5, 6, 7, 8, 9

FDA Drug Label Warning

The FDA label explicitly warns 2:

• "Acute Myopia and Secondary Angle Closure Glaucoma" is a recognized syndrome
• Symptoms include acute onset of decreased visual acuity and/or ocular pain
• Ophthalmologic findings: myopia, anterior chamber shallowing, ocular hyperemia, increased intraocular pressure
• Primary treatment is discontinuation of topiramate as rapidly as possible
• Elevated intraocular pressure, if left untreated, can lead to permanent vision loss

Guideline Recommendations

AACE/ACE Obesity Guidelines (2016)

Grade C recommendation 1:

• Phentermine/topiramate ER should be avoided in patients with glaucoma
• Preferred alternatives: liraglutide 3 mg, orlistat, lorcaserin (no known glaucoma association)
• Naltrexone ER/bupropion ER should be used with caution (also carries angle-closure risk)

AGA Obesity Guidelines (2022)

While phentermine-topiramate ER receives a conditional recommendation for obesity treatment, the guideline explicitly notes 10:

• "Topiramate is teratogenic" and has other safety concerns
• Should be avoided in patients with cardiovascular disease and uncontrolled hypertension
• The glaucoma risk is acknowledged in safety considerations

ADA Diabetes Guidelines (2020)

Lists "Acute angle-closure glaucoma" as a possible safety concern for phentermine/topiramate 11

Ophthalmology Guidelines (2016,2021)

The Primary Angle Closure Preferred Practice Pattern explicitly identifies topiramate as a causative agent 12, 13:

• Specific questioning should address use of topiramate
• Topiramate causes ciliary body edema leading to angle narrowing
• Can precipitate an angle-closure attack

Critical Distinction: This is NOT Primary Angle-Closure

Treatment differs fundamentally from primary angle-closure glaucoma:

WRONG Approach (Primary Angle-Closure Treatment):

• ❌ Laser peripheral iridotomy
• ❌ Pilocarpine (may worsen the condition)
• ❌ Standard antiglaucoma medications alone

CORRECT Approach (Topiramate-Induced):

• ✓ Immediate discontinuation of topiramate 2, 5
• ✓ Cycloplegic eye drops (to relax ciliary body and deepen anterior chamber) 4, 5
• ✓ Corticosteroids (for inflammation) 4
• ✓ IOP-lowering medications as adjunct
• ✓ Resolution typically occurs within 2 days to 2 weeks after drug cessation 5

Clinical Pitfalls to Avoid

1. Bilateral presentation should raise suspicion - Unlike primary angle-closure which is typically unilateral, topiramate-induced glaucoma is characteristically bilateral 4, 5, 6

2. May present without pain - Patients may have painless bilateral vision changes rather than the classic unilateral pain and redness 8

3. Myopic shift is a warning sign - Acute myopia (up to -7.00 diopters) may precede frank angle-closure 5, 8

4. Don't perform iridotomy first - The mechanism is NOT pupillary block, so iridotomy alone will not resolve the condition 4, 7

Alternative Medications for Patients with Glaucoma

Preferred weight-loss medications (no glaucoma association) 1:

• Liraglutide 3.0 mg (GLP-1 agonist)
• Orlistat (lipase inhibitor)
• Lorcaserin (if available; withdrawn in some markets for cardiovascular concerns)

Use with caution:

• Naltrexone ER/bupropion ER - Also carries angle-closure glaucoma risk 11

Bottom Line

Topiramate should NOT be given to patients with glaucoma. The drug is contraindicated in patients with a history of glaucoma due to well-documented risk of acute angle-closure through ciliary body edema and supraciliary effusion. If a patient on topiramate develops acute vision changes, eye pain, or headache, immediate ophthalmologic evaluation and drug discontinuation are mandatory to prevent permanent vision loss. Alternative weight-loss or migraine prophylaxis medications without glaucoma risk should be selected for these patients.